The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has partnered with NTT DATA and CARPL.ai to develop an advanced AI-powered radiology analysis service aimed at transforming cancer diagnosis and treatment. This cutting-edge platform, funded by a three-year grant from the UK’s National Institute for Health and Care Research (NIHR), supports research at The Royal Marsden and the Institute of Cancer Research (ICR), including collaborative projects focused on cancers such as sarcoma, lung, breast, brain, and prostate. The AI service enhances the speed and accuracy of identifying imaging biomarkers, enabling faster diagnoses, more precise evaluations, and better-targeted treatments.
AI and MLOps Technology Driving Cancer Imaging Innovation
Built on NTT DATA’s MLOps clinical imaging platform, the service leverages high-performance Dell servers powered by state-of-the-art GPUs, orchestrated through CARPL.ai’s platform. CARPL.ai offers a centralized interface for managing and testing multiple AI algorithms, encompassing a comprehensive library of radiology AI models.
NTT DATA also provides expert imaging AI consulting, assisting Royal Marsden researchers in evaluating AI tools in real-world clinical settings to maximize insights and value from both commercial and in-house AI models.
Expert Perspectives and Future Outlook
Professor Dow-Mu Koh, Functional Cancer Imaging expert at The Royal Marsden, stated:
“By collaborating with NTT DATA and CARPL.ai, we have created a scalable, secure research environment to explore AI’s full potential in cancer diagnosis and treatment.”
Karin Smyth, UK Minister of State for Health, added:
“This collaboration exemplifies the NHS’s 10 Year Health Plan to modernize healthcare through innovative digital technologies, improving early cancer detection and treatment.”
NIHR Scientific Director Mike Lewis emphasized the initiative’s transformative potential for UK cancer care:
“This AI-powered platform is a breakthrough in cancer research that will enhance diagnosis, support NHS staff, and save lives.”
Tom Winstanley, CTO of NTT DATA UK & Ireland, highlighted the project’s commitment to ethical AI use in healthcare innovation.
Empowering Research and Clinical Translation
Once operational, the platform will enable Royal Marsden teams to evaluate diverse AI models across multiple cancer types, providing critical data to improve clinical decision-making. CARPL.ai’s monitoring tools will facilitate real-time model performance tracking, accelerating feedback and clinical translation.
NTT DATA will continue collaborating closely with The Royal Marsden to ensure this AI innovation improves cancer care outcomes and patient experiences across the NHS.
